Biological Considerations in Scaling Up Therapeutic Cell Manufacturing

Cell therapeutics — using cells as living drugs — have made advances in many areas of medicine. One of the most clinically studied cell-based therapy products is mesenchymal stromal cells (MSCs), which have shown promising results in promoting tissue regeneration and modulating inflammation. However...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in pharmacology 2020-05, Vol.11, p.654-654
Main Authors: Cherian, Darshana S., Bhuvan, Tejasvini, Meagher, Laurence, Heng, Tracy S. P.
Format: Article
Language:English
Subjects:
biomanufacturing
bioreactors
cell therapy
immunomodulatory
mesenchymal stromal cells
Pharmacology
secretome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cell therapeutics — using cells as living drugs — have made advances in many areas of medicine. One of the most clinically studied cell-based therapy products is mesenchymal stromal cells (MSCs), which have shown promising results in promoting tissue regeneration and modulating inflammation. However, MSC therapy requires large numbers of cells, the generation of which is not feasible via conventional planar tissue culture methods. Scale-up manufacturing methods (e.g., propagation on microcarriers in stirred-tank bioreactors), however, are not specifically tailored for MSC expansion. These processes may, in principle, alter the cell secretome, a vital component underlying the immunosuppressive properties and clinical effectiveness of MSCs. This review outlines our current understanding of MSC properties and immunomodulatory function, expansion in commercial manufacturing systems, and gaps in our knowledge that need to be addressed for effective up-scaling commercialization of MSC therapy.
ISSN:1663-9812
1663-9812
DOI:10.3389/fphar.2020.00654